TY - JOUR
T1 - An estimation of burden of serious fungal infections in France
AU - Gangneux, J-P
AU - Bougnoux, M-E
AU - Hennequin, C
AU - Godet, C
AU - Chandenier, J
AU - Denning, D W
AU - Dupont, B
AU - LIFE program, the Société française de mycologie médicale SFMM-study group
N1 - Copyright © 2016 Elsevier Masson SAS. All rights reserved.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - OBJECTIVE OF THE STUDY: An estimation of burden of serious fungal diseases in France is essential data to inform public health priorities on the importance of resources and research needed on these infections. In France, precise data are available for invasive fungal diseases but estimates for several other diseases such as chronic and immunoallergic diseases are by contrast less known.MATERIALS AND METHODS: A systematic literature search was conducted using the Web of Science Platform. Published epidemiology papers reporting fungal infection rates from France were identified. Where no data existed, we used specific populations at risk and fungal infection frequencies in those populations to estimate national incidence or prevalence, depending on the condition.RESULTS: The model predicts high prevalences of severe asthma with fungal sensitization episodes (189 cases/100,000 adults per year), of allergic bronchopulmonary aspergillosis (145/100,000) and of chronic pulmonary aspergillosis (5.24/100,000). Besides, estimated incidence for invasive aspergillosis is 1.8/100,000 annually based on classical high risk factors. Estimates for invasive mucormycosis, pneumocystosis and cryptococcosis are 0.12/100,000, 1/100,000 and 0.2/100,000, respectively. Regarding invasive candidiasis, more than 10,000 cases per year are estimated, and a much higher number of recurrent vaginal candidiasis is probable but must be confirmed. Finally, this survey was an opportunity to report a first picture of the frequency of tinea capitis in France.CONCLUSION: Using local and literature data of the incidence or prevalence of fungal infections, approximately 1,000,000 (1.47%) people in France are estimated to suffer from serious fungal infections each year.
AB - OBJECTIVE OF THE STUDY: An estimation of burden of serious fungal diseases in France is essential data to inform public health priorities on the importance of resources and research needed on these infections. In France, precise data are available for invasive fungal diseases but estimates for several other diseases such as chronic and immunoallergic diseases are by contrast less known.MATERIALS AND METHODS: A systematic literature search was conducted using the Web of Science Platform. Published epidemiology papers reporting fungal infection rates from France were identified. Where no data existed, we used specific populations at risk and fungal infection frequencies in those populations to estimate national incidence or prevalence, depending on the condition.RESULTS: The model predicts high prevalences of severe asthma with fungal sensitization episodes (189 cases/100,000 adults per year), of allergic bronchopulmonary aspergillosis (145/100,000) and of chronic pulmonary aspergillosis (5.24/100,000). Besides, estimated incidence for invasive aspergillosis is 1.8/100,000 annually based on classical high risk factors. Estimates for invasive mucormycosis, pneumocystosis and cryptococcosis are 0.12/100,000, 1/100,000 and 0.2/100,000, respectively. Regarding invasive candidiasis, more than 10,000 cases per year are estimated, and a much higher number of recurrent vaginal candidiasis is probable but must be confirmed. Finally, this survey was an opportunity to report a first picture of the frequency of tinea capitis in France.CONCLUSION: Using local and literature data of the incidence or prevalence of fungal infections, approximately 1,000,000 (1.47%) people in France are estimated to suffer from serious fungal infections each year.
KW - Aspergillosis
KW - Candidiasis
KW - Cryptococcosis
KW - France
KW - Mucormycosis
KW - Pneumocystosis
KW - Tinea capitis
UR - http://www.scopus.com/inward/record.url?scp=84999287859&partnerID=8YFLogxK
U2 - 10.1016/j.mycmed.2016.11.001
DO - 10.1016/j.mycmed.2016.11.001
M3 - Article
C2 - 27887809
SN - 1460-2709
VL - 26
SP - 385
EP - 390
JO - Medical Mycology
JF - Medical Mycology
IS - 4
ER -